Alliance for Pandemic Preparedness

September 8, 2020

Safety and Immunogenicity of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia

Category:

Topic:

  • Findings from two, non-randomized phase 1/2 studies (n=38 per study) conducted in Russia of recombinant vaccines based on adenovirus type 5 (rAd5) and type 26 (rAd26) show that both vaccine formulations were well tolerated with no serious adverse events reported.
  • All participants produced SARS-CoV-2 antibodies, and the vaccines induced strong humoral and cellular immune responses in participants.

Logunov et al. (Sept 4, 2020). Safety and Immunogenicity of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia. The Lancet. https://doi.org/10.1016/S0140-6736(20)31866-3